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Abstract
In elderly acute myeloid leukemia (AML) patients post-remission treatment options are associated with high comorbidity 
rates and poor survival. Dendritic cell (DC)-based immunotherapy is a promising alternative treatment strategy. A novel 
allogeneic DC vaccine, DCP-001, was developed from an AML-derived cell line that uniquely combines the positive features 
of allogeneic DC vaccines and expression of multi-leukemia-associated antigens. Here, we present data from a phase I study 
conducted with DCP-001 in 12 advanced-stage elderly AML patients. Patients enrolled were in complete remission (CR1/
CR2) (n = 5) or had smoldering disease (n = 7). All patients were at high risk of relapse and ineligible for post-remission 
intensification therapies. A standard 3 + 3 dose escalation design with extension to six patients in the highest dose was 
performed. Patients received four biweekly intradermal DCP-001 injections at different dose levels (10, 25, and 50 million 
cells DCP-001) and were monitored for clinical and immunological responses. Primary objectives of the study (feasibility 
and safety) were achieved with 10/12 patients completing the vaccination program. Treatment was well tolerated. A clear-
cut distinction between patients with and without detectable circulating leukemic blasts during the vaccination period was 
noted. Patients with no circulating blasts showed an unusually prolonged survival [median overall survival 36 months (range 
7–63) from the start of vaccination] whereas patients with circulating blasts, died within 6 months. Long-term survival was 
correlated with maintained T cell levels and induction of multi-functional immune responses. It is concluded that DCP-001 
in elderly AML patients is safe, feasible and generates both cellular and humoral immune responses.
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Introduction
Acute myeloid leukemia (AML) most commonly affects 
the elderly population with a median age of around 
67 years [1, 2]. Current AML treatment relies largely on 
intensive chemotherapy and allogeneic hematopoietic 
stem cell transplantation (HSCT), which is unsuccessful in 
60–80% of patients due to persistence of measurable resid-
ual disease (MRD) [3, 4]. Particularly in elderly patients, 
these strategies are associated with high comorbidity rates 
and the 5-year overall survival in this population remains 
poor (10–15% in patients > 65). Therefore, new treatment 
strategies are urgently needed.
Immunotherapeutic approaches aiming to eradicate 
MRD through activation of  CD8+ cytotoxic T-lympho-
cytes (CTL), contribute to improved disease outcome 
[5]. Such anti-leukemia CTL are most effectively primed 
by the most powerful antigen-presenting cell identified 
to date, i.e., the dendritic cell (DC). Clinical trials have 
shown that DC vaccination is safe, has hardly any side 
effects and induces immune responses [6, 7]. However, 
autologous DC vaccination is cumbersome, costly and 
logistically complex. Moreover, clinical efficacy has 
proven limited, most probably due to the fact that most 
trials were performed with single-antigen-loaded DC. As 
an alternative, the use of autologous or allogeneic whole 
tumor cell lysates or tumor-derived peptide pools as a 
source of tumor-associated antigens (TAAs) for DC load-
ing has been extensively explored [8, 9]. These formula-
tions cover a wide range of both uncharacterized and char-
acterized tumor antigens, thereby reducing the chance of 
post-vaccination immune escape. Unfortunately, feasibility 
was often limited by availability of sufficient numbers of 
autologous or allogeneic tumor cells [10].
Allogeneic DCs have been reported to induce stronger 
antigen-specific immune responses than autologous DC 
because they trigger a broader  CD8+ T cell immune reper-
toire, including tumor reactive T cells, and a broad inflam-
matory response by polyclonal stimulation of allogeneic T 
cells [11, 12]. The indirect antigen presentation route by 
host DCs and strong Th1 cell differentiation and activa-
tion in response to allo-antigens, will add to the T cell-
mediated antitumor response.
A novel DC vaccine, DCP-001, was developed that 
uniquely combines the positive features of allogeneic DC 
vaccines and multi-antigen-expressing tumor cell vaccines. 
DCP-001 consists of mature DC generated through differ-
entiation and maturation of the AML cell line DCOne and 
as such harbors AML-associated antigens.
Here, we report the results of a phase-I safety and 
feasibility trial of DCP-001 vaccination in advanced-
stage elderly AML patients ineligible for standard 
post-remission therapies. Besides clinical safety, the 
results demonstrate biological efficacy of the vaccine 
with the induction of both specific T cell and humoral 
responses. Moreover, clinical efficacy is suggested by an 
unexpectedly sustainable clinical benefit observed in five 
out of the twelve enrolled patients.
Materials and methods
Study design and patient inclusion
A phase I feasibility and safety trial was conducted from 
March 2011 to March 2013. The set-up followed a standard 
3 + 3 dose escalation design with extension to six patients in 
the highest non-toxic dose level. Main inclusion criteria were 
either AML in second complete remission (CR2), (relapsed) 
smoldering AML, or de novo AML in CR1, all not eligible 
for additional intensification therapy. Patient characteristics 
are listed in Table 1. Exclusion criteria included uncon-
trolled active infection, previous immunotherapy in the last 
3 months, and previous allogeneic peripheral stem cell trans-
plantation. Patients received DCP-001 vaccinations at days 
0, 14, 28 and 42. Skin testing was performed at days 2, 49 
and 51. For immunomonitoring, samples were taken before 
first vaccination, 1 week after the fourth vaccination (day 
49), and 12 weeks after the fourth vaccination (day 126). 
Subsequently, extended follow-up until death was performed 
to evaluate clinical outcome.
The primary endpoints were safety and feasibility, sec-
ondary endpoints included evaluation of immune responses.
DCP-001 production
DCP-001 was manufactured according to good manufac-
turing practice (GMP) regulations following previously 
described protocols [13, 14]. In brief, the cells were cultured 
in a cocktail of GM-CSF, TNFα, and IL-4 in the presence 
of mitoxantrone to accelerate DC differentiation, followed 
by maturation in the presence of prostaglandin-E2, TNFα, 
and IL-1β. Quality control (QC) included microbiological 
controls and QC release tests for cell viability and num-
ber, phenotype (by flow cytometry, based on expression of 
CD1a, Langerin, and MHC and costimulatory markers), 
and potency through T cell priming in a mixed leukocyte 
reaction (MLR), and migration in response to the lymph 
node homing chemokines MIP3β and 6-CKine in a trans-
well assay—all as described earlier [13, 15–17]. In total, 
three different GMP batches were prepared and shown to be 
highly comparable in terms of phenotype and functional-
ity (Fig. 1). Clinical lots were gamma irradiated to prevent 
cell replication and cryopreserved in Cryostor CS10 (Biolife 
Solutions, USA).
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DCP-001 administration
Patients received four biweekly intradermal (i.d.) DCP-
001 vaccinations (2–4 four injections of 0.5 mL each) in 
the upper leg. The first cohort (n = 3; patient 001, 002, 
004) received 10 million cells/vaccination, the second 
cohort (n = 3; patient 005, 006, 007) 25 million cells/
vaccination, and the third cohort (n = 3 patient 008, 011, 
012) received 50  million cells/vaccination. The third 
cohort was extended with three patients (patient 013, 014, 
015). Delayed-type hypersensitivity reactions were meas-
ured in the lower arm. Of note, patient 001 received two 
booster vaccinations of 10 million cells, 13.5 months after 
the fourth vaccination (t = 0) at 2-week intervals. At this 
point as well as 21 and 70 days later, blood was drawn for 
immunomonitoring.
Clinical sample handling and storage
Peripheral blood mononuclear cells (PBMC) were isolated 
by Ficoll density separation [16] at day 0, day 49 (1 week 
after fourth vaccination) and day 126 (12 weeks after fourth 
vaccination). Serum was collected at similar time points and 
stored at − 80 °C. Monocytes and peripheral blood lympho-
cytes (PBL) were isolated from PBMC by CD14 magnetic 
bead isolation (MACS, Miltenyi Biotec, Germany) follow-
ing manufacturers’ instructions. PBMC, PBL and monocytes 
were cryopreserved in C.T.L. CryoABC cryopreservation 
medium (ImmunoSpot, Cleveland, USA).
HLA typing
At screening, all patients were serologically typed for HLA 
class I and II by Sanquin, Amsterdam, Netherlands.
Delayed‑type hypersensitivity (DTH) testing
DTH testing was performed to monitor patient’s cell-medi-
ated immunity before and after treatment by i.d. injection of 
DCP-001 (2 million cells/0.2 mL) or vehicle control (CS10), 
at start of vaccination and 7 days after the fourth vaccina-
tion. Induration was measured in mm across two diameters 
after 48 h. Results were expressed as the mean induration. 
Positive DTH reactions were defined as > 5 mm diameter 
induration. A difference between first (Pre-Vacc) and second 
(Post-Vacc) skin test reactions exceeding 50% of the Pre-
Vacc measurement, with a Post-Vacc reactivity > 5 mm, was 
considered to reflect positive vaccination reactivity.
Immunohistochemistry of DTH site biopsies
Immunohistochemistry analysis was performed on biopsies 
taken from the DTH sites under local anesthesia. Biopsies 
were formalin-fixed/paraffin-embedded and stained with the 
following antibodies as previously described [18–21]: CD1a, 
CD3, CD4, CD8, CD83, DC-SIGN, Granzyme B, FoxP3, 
CD45RO, TIA, CD56 and langerin. Positively stained cell 
rates were assessed independently by two observers and 
classified as negative (−), low (±), moderate (+), high (++) 
or very high-infiltration rate (+++). In case of inconsistent 
Table 1  Patient characteristics
MD missing data, Mo months, No number
a Died before end of study
Patient no. Age Sex Time between AML 
diagnosis and study entry 
(Mo)
Disease status Dead/alive at 
end of study
% Blasts in bone mar-
row (cytomorphology)
At study entry At end of study At study entry At 
end of 
study
DC-001 66 F 8 AML relapse/smoldering CR Alive 7 3
DC-002 70 M 7 AML relapse/smoldering Disease progression Dead 53 89
DC-004 72 F 45 AML in CR2 CR Alive 2 3
DC-005 74 M 75 AML relapse/smoldering Pneumonia Dead 58 MDa
DC-006 69 F 18 AML relapse/smoldering Disease progression Alive 14 80
DC-007 74 F 14 AML relapse/smoldering Smoldering disease Alive MD 7
DC-008 64 F 7 de novo AML, in CR1 CR Alive 0 MD
DC-011 57 M 11 de novo AML, in CR1 Endocarditis Dead 1 MDa
DC-012 70 M 22 AML relapse/smoldering Disease progression Alive 5 31
DC-013 65 M 3 de novo AML, in CR1 CR Alive 2 2
DC-014 67 M 20 AML relapse/smoldering Disease progression Dead 29 MDa
DC-015 68 M 5 de novo AML, in CR1 CR Alive 7 1
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results between the two observers, assessment by a third 
observer was carried out and subsequent consensus reached.
T cell proliferation and cytokine analysis
Isolated PBL were thawed, CFSE labeled (2 µM) and co-
cultured for 7–10 days with different doses of irradiated 
(50 Gy) monocytes, DCP-001 and DCOne progenitor cells. 
Cells were stained with fluorochrome-labeled anti-CD3 and 
anti-CD8 antibodies and proliferation of  CD4+ (i.e.,  CD8−) 
and  CD8+ T cells was measured on a FACSCalibur, using 
Cellquest software.
The threshold for a positive response was arbitrarily set at 
20% proliferation of the responder T cells with low (< 5%) 
proliferation rates against autologous monocytes. A positive 
vaccination-induced response was defined as an increase in 
Post-Vacc proliferation of ≥ 10%. Similarly, an MLR was 
carried out with PBL from one pre-specified healthy donor 
to qualify DCP-001. For cytokine analysis, supernatant was 
harvested and used for T cell cytokine analysis using the 
Th1/Th2/Th17 Cytometric Bead Array (CBA) kit according 
to the manufacturer’s instructions (BD Biosciences).
In vitro T cell stimulation and IFNγ ELISpot analysis
DCP-001 induced T cell responses to full-length TAAs 
WT-1, PRAME, MAGE-A3 or NY-ESO-1 were meas-
ured by IFNγ ELISpot assay as previously described [16, 
22, 23]. In brief, overlapping 15-mer peptide pools (JPT 
peptide technologies, Berlin, Germany) were loaded onto 
autologous irradiated PBMC which were co-cultured with 
an equal number of non-irradiated PBMC for 10 days. At 
day 10, the cells were seeded in an ELISpot plate in the 
presence of the corresponding peptide pools for 24 h after 
which an ELISpot read-out was performed. A 15-mer CEFT 
peptide pool served as a positive recall antigen response con-
trol. PHA was used for technical and sample quality con-
trol. The ELISpot assay was performed using an anti-IFNγ 
mAb pair (Mabtech, Nacka, Sweden [23]). T cell activity 
was expressed as the number of spots per 100,000 T cells 
(determined by CD3 FACS analysis at the time of ELISpot 
read-out) and considered positive when, (1) the number of 
spots in the TAA test condition was significantly higher than 
the number of spots in the HIV control condition (unpaired 
Student’s t test), (2) the mean number of spots of the test 
condition exceeded the number of spots of the control con-
dition by at least twofold and (3) the absolute difference in 
number of spots between the test and control condition was 
at least five.
Serology
Vaccination-induced antibodies against DCOne progeni-
tor and, if available, autologous blast lysates were meas-
ured in serum by western blot analysis using denaturing 7% 
SDS–polyacrylamide gels and PVDF protein membranes 
(BioRad). Following blocking, the membranes were incu-
bated with pre- and post-vaccination sera and HRP-conju-
gated anti-hIgG/A/M as secondary antibody (Dako). Blots 
were developed with chemoluminescence substrate (GE 
Healthcare). Increased intensity or appearance of new bands 
in Post-Vacc samples denoted DCP-001 vaccination-induced 
antibody responses.
Statistical analyses
Differences between immune parameters were assessed 
before and after treatment with two-sided t test. T cell 
response rates (overall T cell scores) between short- and 
long-term survivors were compared using the Fisher’s exact 
test. For data collection, Microsoft Excel (version 2007) was 
used and for statistical analysis GraphPad Prism software 
(version 5.0). Differences were considered significant when 
p < 0.05.
Results
DCP‑001: phenotypic and functional specifications
DCP-001 consists of mature DC differentiated from the 
AML cell line DCOne which expresses multiple TAAs 
(e.g., WT-1, PRAME, data not shown). In addition, DCP-
001 cells display high expression levels of CD1a, langerin, 
a wide range of costimulatory molecules, and MHC class I/
II molecules (Fig. 1a). The manufactured DCP-001 batches 
Fig. 1  Phenotype, T cell stimulatory and migratory capacity of DCP-
001. DCP-001 was analyzed for a expression of dendritic cell mark-
ers and costimulatory molecules, b its allogeneic T cell stimulatory 
capacity and c ability to migrate to lymph node homing chemokines 
6CKine and MIP3ß. a Expression levels of CD1a, langerin, and 
several costimulatory molecules were analyzed by flow cytometry; 
isotype-matched controls (shaded histograms) and the tested mark-
ers (closed histograms) are indicated. Mean fluorescence is shown in 
each panel. b Allogeneic T cell stimulatory capacity was analyzed by 
MLR. Proliferation of CFSE-labeled PBL was assessed after culture 
for 6 days with a dose range of DCP-001 cells as stimulators. CFSE 
dilution was used as a measure of percentage of proliferated cells. 
Results of three different DCP-001 batches, each as mean ± SD per-
formed in six replicates. c Analysis of migratory capacity of DCP-
001. Cells were analyzed for their capacity to migrate toward LN 
homing chemokines in a trans-well migration assay. Migration toward 
medium, 6CKine and MIP3ß is given as a percentage of migrated 
cells. Data represent mean ± SD of three independent batches of 
DCP-001 each performed in triplicate. Each batch refers to a clinical 
batch. d QC release on phenotype for DCP-001 batches. Results show 
the mean ± SD of three independently produced clinical batches. The 
%CV between the batches is < 10% pointing to a high-batch compa-
rability
◂
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passed QC release tests, including sterility and endotoxin 
level (< 5 EU/mL). Cell number, viability, phenotypic 
expression and potency (migration, MLR) were evaluated 
directly after thawing. DCP-001 cells displayed a consistent 
ability to prime allogeneic T cells (Fig. 1b) and to migrate 
in response to the chemokines 6Ckine and MIP3β (Fig. 1c), 
both involved in homing to the paracortical T cell areas of 
lymph nodes. Figure 1d depicts the phenotype used for QC 
release and demonstrates a very high consistency between 
the 3 independently produced clinical batches.
Patient characteristics and on‑treatment disease 
development
The safety, feasibility, and biological effects of DCP-001 
vaccination were investigated in 12 elderly AML patients 
in a 3 + 3 dose design. Final assessment was done after 126 
days, i.e., 3 months after the last (4th) vaccination. Patient 
characteristics are listed in Table 1. Blast percentages as 
listed in Table 1 were based on standard cytomorphology. 
For listing of prior therapies and cytogenetic features of the 
patient’s tumors, we refer to Supplementary Table 1. Patients 
(age range 58–71), enrolled were either in CR1/CR2 (n = 5) 
or had smoldering disease (n = 7). Twelve patients initiated 
vaccination of which ten patients received all four vacci-
nations (83,3%) and two patients (002 and 011) received 
three vaccinations. One patient discontinued due to disease 
progression (002) and one patient (011) due to a candida 
endocarditis.
Safety and feasibility
DCP-001 vaccination was well tolerated, safe and feasi-
ble. Six patients experienced severe adverse events (SAE) 
during the study (002, 004, 005, 007, 011 and 014), only 
one (002) was judged to have a possible relationship to 
study treatment (diabetes insipidus). This could possibly 
represent a vaccine-induced autoimmune response. All 
others were considered unrelated or unlikely to be related 
to study treatment. Two patients died before completing 
the study due to pneumonia (005) and disease progres-
sion (014). Neither of these deaths were related to study 
treatment. Two patients discontinued study treatment (see 
above); SAEs in patients 004 (myocardial infarct) and 
007 (vasovagal collapse) did not lead to discontinuation 
and both patients in fact proved to be long-term survivors 
(Fig. 2). The distribution of AEs between cohorts was 
uneven but there was no trend suggesting a dose–response 
relationship for AE occurrence. AEs were of CTC grade 
1 or 2 and most were judged as unrelated to study treat-
ment. The most common AEs were injection site reac-
tions (6 patients), anemia (4 patients), thrombocytope-
nia (3 patients), fatigue (3 patients), pain in extremity (3 
patients), and nausea (3 patients).
Clinical outcome
At the end of the study (day 126), 9 out of 12 (75%) 
patients were alive. Eight patients completed all assess-
ments and for those four patients who did not complete 
the study, reasons were disease progression (002), death 
due to disease progression (014), pneumonitis/pneumonia 
(005) and candida endocarditis (011).
Six out of 12 patients were in CR (i.e., undetectable 
AML blasts in blood and < 5% in bone marrow) at study 
end and 5/12 experienced persistent disease (Table 1). 
All patients, except for one, who were in CR at end of 
study, were in CR1 or CR2 at baseline. All but one of 
the patients with smoldering disease at study entry, had 
persistent disease at the end of the study (Table 1). One 
patient (001) with smoldering disease reached CR at the 
Fig. 2  Detectability of leukemic 
blasts in patients is related 
to post-vaccination survival. 
Shown is overall survival since 
start of vaccination; patients 
were subdivided by the presence 
of detectable leukemic blasts 
in peripheral blood during 
treatment (dotted line). Death is 
indicated by black box; causes 
of death are listed. PB periph-
eral blood
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due to infections
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end of the study. This patient had circulating blast counts 
of 0.05 × 109/L and bone marrow blasts of 7% at baseline. 
No clear relationship between clinical outcome and admin-
istered DCP-001 dose was apparent.
Follow-up
The study was formally completed in March 2013 but all 
patients were clinically followed until death. At present 
(December 2017) one patient is still alive. Based on the 
presence or absence of circulating leukemic blasts patients 
could be divided into two groups, which corresponded 
to short-(≤ 6 months, median overall survival 3 months, 
range 2–6 months) and long-term survivors (> 6 months, 
median overall survival 36 months, range 7–63 months), 
respectively (Fig. 2). The two groups showed strikingly 
different patterns in peripheral leukemic blast and T cell 
counts during treatment (Fig. 3). Patients with detect-
able peripheral blast died within 6 months post-treatment 
(short-term survivors). Patients without detectable leuke-
mic blasts in peripheral blood (or rapidly dropping below 
the detection threshold) showed remarkably prolonged 
survival (Fig. 3a), with one patient still alive at the time 
of writing and 64 months after study entry and the other 
patients surviving for 7, 36, 22, 63, and 36 months (Fig. 2). 
Long-term survival was accompanied by maintained lev-
els of T cells. In patients with short-term survival and 
detectable circulating blasts, T cell levels dropped pre-
cipitously (Fig. 3b).
Biological efficacy: immune response monitoring
Immune monitoring was performed to evaluate DCP-001 
vaccination-induced immune responses and to identify pos-
sible relationships to clinical outcome. Patients with detect-
able blasts at study entry (002, 005, 006, 012, and 014) 
experienced rapidly dropping T cell frequencies (Fig. 3b) 
which excluded the possibility to perform all in vitro T cell-
based assay in some cases and to draw clear conclusions on 
immune responses between the two groups. An overview of 
T cell-related immune data pre- and post-vaccination (day 
0, day 49 and day 126) is summarized in Table 3 and are 
further explained below.
HLA-compatibility between DCP-001 and patients
The HLA type of DCP-001 is HLA-A2,3, -B44, 
-DRB1:10,11 and -DQB1:05‚03. HLA matches varied from 
1 to 5 but the number of (mis)matches showed no clear rela-
tionship with survival (Table 2). None of the patients showed 
a full mismatch, i.e., not expressing any of the DCP-001 
HLA alleles (Table 2). Moreover, no correlations between 
degree of HLA match and observed immune responses were 
found.

















































































Fig. 3  Leukemic blast and T cell rates in short- versus long-term sur-
vivors. Absolute numbers of leukemic blasts in peripheral blood over 
treatment (in days, EOS = end of study) in a short-term (less than 
6 months) survivors and in b long-term (more than 6 months) survi-
vors. T cell rates (as percentage of PBMC) in c short-term (less than 
6 months) survivors and in d long-term (more than 6 months) survi-
vors. PB peripheral blood
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Antigen-specific immune responses
T cell reactivity by IFNγ ELISpot analysis after in vitro 
stimulation was assessed against the AML-related antigens 
WT-1 and PRAME, both of which were expressed by the 
DCP-001, as well as against NY-ESO-1 and MAGE-A3. 
NY-ESO-1 and MAGE-A3 are not expressed by DCP-001 
but were included to monitor for possible epitope spread-
ing, i.e., T cell responses primed against epitopes released 
from the patients’ autologous blasts after a successful DCP-
001 induced anti-AML immune response. Indeed, instances 
of induced de novo or boosted pre-existent responses were 
found post-vaccination for all four TAAs (Fig. 4a, b). Over-
all, four out of eight evaluable patients showed DCP-001 
induced or enhanced WT-1, PRAME, MAGE-A3, or NY-
ESO-1 responses (Table 3). An unexpectedly high number 
of patients (3 out of 3) showed enhanced post-vaccination 
responses against NY-ESO-1, of which one was de novo 
primed (Fig. 4b). For one patient (004), also pre-and post-
treatment bone marrow samples were available revealing 
upregulated NY-ESO-1 T cell reactivity at day 126 (Sup-
plementary Fig. 1). All tested patients showed pre-existent 
reactivity to the CEFT recall antigen pool, which was main-
tained over treatment, indicating good immune competence 
(data not shown). An overview of pre- and post-vaccination 
ELISpot responses of all four patients with post-vaccination-
positive ELISpot reactivities (expressed as specific T cell 
numbers per  105 T cells) are shown in Supplementary Fig. 2.
Antibody responses generated against DCOne progeni-
tor and autologous blast antigens was evaluated in 10/12 
patients. Five patients showed an increased response with 
bands gaining in intensity or new bands appearing on the 
blots, denoting vaccination-induced humoral responses 
(Fig. 4c). Specificity of the responses, in terms of the iden-
tity of the recognized antigens, remains to be determined. 
Importantly, induced antibody responses against autolo-
gous blasts were also observed in two out of three evalu-
able patients (Fig. 4c), which demonstrates the induction of 
immunity against autologous AML blasts by the allogeneic 
DCP001.
DTH reactivity
In the DTH tests, 5 of 11 evaluable patients had an increase 
of ≥ 50% in the mean diameter of induration at day 51 
compared to baseline, indicating DCP-001-induced T cell 
response (Table 3). Importantly, no reactivity to the Cryos-
tor vehicle control was ever observed (data not shown). Of 
the 7 patients who did not have an increase at day 51 com-
pared to baseline, all showed a baseline reaction of at least 
4 mm (range 3.5–15 mm) which points to a pre-existing 
immunity to components of the DCP-001. This could be 
an allo-reaction but also a response to TAAs in the vac-
cine. Evidence for vaccination-induced increases in DTH 
reactivity was mostly found among long-term (> 6 months) 
survivors (Table 3).
Immunohistochemistry
Immunohistochemical assessment of DTH punch biopsies 
was performed for T cell and DC influx in 9 out of 12 
patients at day 2 and day 51 (Fig. 4d). All of these patients 
showed an increased influx of activated T cells in response 
to the vaccine as compared to the Cryostor vehicle control 
in both the superficial and deep dermis and to a similar 
extent at d2 (pre-vaccination) and d51 (post-vaccination) 
(Supplementary Fig. 3). Irrespective of the dosage used, 
DCP-001 vaccination also resulted in increased TIA or 
Granzyme B-positive cytotoxic T cell infiltration in indi-
vidual cases (Fig. 4d and Supplementary Fig. 3a). No 
Table 2  HLA typing of patients
ID identity, MD missing data, No number
Patient  IDa HLA-A HLA-B HLA-C HLA-DQ HLA-DR No. of 
HLA 
matches
DCP-001 A2, 3 B44 C4, 7 DQ3, 5 DR10, 11
Short survivors ≤ 6 months 002 A1‚ 3 B7‚ 8 C7 DQ2, 6 DR3, 15 2
005 A1‚ 25 B18, 56 MD MD MD MD
006 A2, 32 B40, 44 C3, 5 DQ2, 4 DR3, 8 2
012 A2, 3 B7, 15 C7, 3 DQ3 DR4, 9 3
014 A1, 3 B15, 39 C3, 5 DQ4, 6 DR8, 13 1
Long survivors > 6 months 001 A3, 24 B15, 44 C3, 5 DQ3, 5 DR4, 14 4
004 A2 B27, 40 C1, 3 DQ5‚ 3 DR1, 4 2
007 A2, 31 B15, 40 C3, 3 DQ3, 5 DR4, 16 3
008 A2, 32 B7, 44 C7, 5 DQ3, 6 DR12, 15 4
013 A2, 68 B7, 44 C7, 7 DQ3, 6 DR11, 15 5
015 A3, 11 B44, 55 C3, 3 DQ3, 5 DR4, 16 4
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 CD56+ NK cell infiltration was observed. In addition, a 
selective increase of  CD4+ and  CD45RO+ infiltrate (in 
particular in the higher dose levels) in the superficial 
dermis was observed at the DCP-001 delivery site that may 
point to a more active effector-memory Th-cell compart-
ment after vaccination (Supplementary Fig. 3b).
Fig. 4  Immune responses induced by the DCP-001. Representative 
examples are shown of poly-functional immune responses elicited 
by DCP-001 vaccination. Pre- and post-vaccination T cell responses 
after in  vitro restimulation in an IFNγ ELISpot read-out against a 
WT-1 and PRAME in patient 012 and against b NY-ESO-1 and 
MAGE-A3 in patient 015. c Examples of enhanced (closed arrows) 
and de novo serological responses post-vaccination against DCOne 
progenitor and autologous AML blast lysates in patient 006. d 
Examples of CD4, CD8, and Gr-B immunohistochemical staining of 
immune infiltrates in the dermis of DCP-001 DTH biopsies pre- and 
post-vaccination (magnification ×100). e Proliferation (by CFSE dilu-
tion read-out) of  CD4+ or  CD8+ T cells from peripheral blood (013), 
pre- (t = 0) and post-vaccination (t = 49 or 126 days), against DCP-
001 mature DC (top panels), or their DCOne progenitors (bottom left 
panel) or IFNγ release in response to DCP-001 (right bottom panel); 
autologous monocytes served as non-tumor controls. Gr-B Granzyme 
B
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T cell reactivity to DCP-001 and its DCOne progenitors 
by MLR
The proliferative T cell capacity in response to DCP-001 
and DCOne progenitor cells was analyzed in 9/12 patients. 
Seven of these patients showed pre-existent T cell responses 
(proliferation rate ≥ 20%), as is to be expected for an alloge-
neic vaccine. Increased proliferative responses (either CD4 
or CD8) against DCP-001 cells and/or DCOne progeni-
tor cells upon vaccination were observed in 6/9 evaluable 
patients (Table 3; Fig. 4e), whereas in none of the patients 
reactivity to autologous monocytes was observed. Nota-
bly, in five cases, increased post-vaccination reactivity to 
DCOne progenitors was observed, which almost exclusively 
involved  CD8+ T cells (data not shown). This observation is 
highly suggestive for the induction of a  CD8+ effector T cell 
response to AML blasts.
CBA analysis further showed a measurable IFNγ response 
against DCP-001 in 5/9 patients (for a representative result, 
see Fig. 4e), accompanied by IL-2 release in three cases. 
In two additional patients, also post-vaccination IL-4, IL-6, 
IL-17 or IL-10 responses were detected (Supplementary 
Fig. 5). These results demonstrate the induction of Th1 or 
mixed Th1/Th2/Th17 responses by DCP-001.
Immune reactivity induction upon a booster vaccination 
regimen
Patient 001 received two booster vaccinations of 10 million 
DCP-001 cells 13.5 months after initial treatment. Remark-
ably, whereas this patient did not show DCP-001-induced 
immune reactivity after the first four vaccinations, after 
receiving the booster vaccination she developed de novo 
antibody responses both to her autologous leukemic blasts 
and to DCOne progenitors (Supplementary Fig. 4) as well 
as proliferative  CD8+ T cell responses against the DCP-001 
(Table 3).
DCP-001-induced T cell reactivity in relation to survival
Overall, the immune-monitoring data clearly demonstrate 
DCP-001-induced T cell reactivity. When results from all 
T cell-related assays were combined, an “Overall T cell 
Score” was derived (Table 3). To arrive at the T cell score, 
vaccination-induced T cell immune responses were scored in 
four different categories, i.e., (1) T cell proliferative response 
to the DCP-001, (2) a positive post-vaccination leukemia-
associated antigen-specific ELISpot reactivity, (3) increased 
number of infiltrating  CD4+ or  CD8+ T cells in the superfi-
cial dermis of the post-vaccination DTH site (by immuno-
histochemistry, see Supplementary Fig. 3b and 4) post-vac-
cination increase in DTH site induration. Positive responses 
in each of the categories (as defined in the “Materials and 
methods”) resulted in a point per category, with a low score 
of 0 out of 4 and a possible highest T cell score of 4 out of 
4. These analyses demonstrated significantly lower scores (5 
positive assays out of 15 conducted) in short-term survivors 
(≤ 6 months) versus long-term survivors. (> 6 months, 15 
positive assays out of 22 conducted, p = 0.049 by two-sided 
Fisher’s exact test).
Discussion
Persistent MRD after induction chemotherapy poses a major 
challenge in the treatment of AML. Particularly in older 
patients, who are not eligible for post-remission intensifica-
tion treatments such as allogeneic hematopoietic stem cell 
transplantation, overall survival rates are dismal (15–20% 
at 2 years) [24–27]. Successful immunotherapy can offer 
long-term protection against outgrowth of MRD through 
the activity of memory T cells that can specifically recog-
nize and eliminate leukemic blasts. That this may present 
an effective treatment option is supported by the apparent 
dependence of the efficacy of allogeneic hematopoietic stem 
cell transplantation on the graft–versus–leukemia effect, 
mediated by T cell immunity against histocompatibility-
mismatched leukemic blasts [28]. Unfortunately, transplan-
tation-associated graft–versus–host disease is associated 
with considerable morbidity and mortality in patients [29, 
30]. In AML, DC-based vaccines have, therefore, been clini-
cally explored as an alternative means of kick starting cell-
mediated immunity against leukemia.
Previous clinically tested AML-targeted DC vaccines 
have mostly consisted of autologous monocyte-derived 
DC, either loaded with single-antigen-derived peptides or 
mRNA [7, 31–33] or autologous AML blast lysates [34, 
35], fused to autologous AML blasts [36], or derived from 
autologous blasts that were differentiated into DC-like cells 
[37]. These approaches have led to varying levels of clini-
cal efficacy with reports of dropping peripheral blast counts 
and prolonged overall survival in treated individual patients. 
Approaches employing autologous blasts rely on TAAs and 
neo-antigens selectively expressed in autologous tumors and 
provide a poly-epitope-based personalized vaccine that can 
trigger both Th, CTL and humoral immunity. A disadvan-
tage of this personalized approach is the laborious and costly 
vaccine production process and its inherent variability in 
quality [9, 37]. As AML has a low mutational burden result-
ing in an expected low number of neo-epitopes [38], vacci-
nation efficacy will most likely depend on shared common 
TAAs. As such a strong case can be made for an allogeneic 
DC-based approach that can offer a highly standardized off-
the-shelf platform.
DCP-001 expresses a range of shared TAAs and HLA 
haplotypes that together cover more than 70% of the 
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Caucasian population. It presents a highly potent, standard-
ized and fully scalable vaccine platform that is widely appli-
cable. Here, data of a phase-I trial of DCP-001 vaccination 
in elderly AML patients in CR1/CR2 or with smoldering 
disease are presented. The vaccine proved safe and a treat-
ment regimen of four biweekly i.d. DCP-001 injections was 
feasible, thus meeting the primary objectives of the study. 
The obtained results further suggest that in patients with 
demonstrable immune competence and maintained periph-
eral T cell rates, DCP-001 can induce a multi-functional 
immune response to the vaccine, its AML progenitors, com-
mon shared leukemia-associated antigens (LAA), as well 
as to antigens in autologous leukemic blasts. Although the 
study size is too small to draw definitive conclusions, the 
observed immune responses may have translated into a long-
term clinical benefit in those patients who were in CR at the 
time of vaccination, and therefore, would have been in a less 
immune-suppressed state. Typically, the inclusion criteria 
employed in this trial would select for patients with an aver-
age life expectancy of 3–6 months [1, 2, 39]. It is, therefore, 
remarkable that 6 of the 12 enrolled patients in this trial 
survived for more than 6 months after start of treatment 
(Fig. 2, median overall survival 36 months), with one patient 
still alive at the time of writing. Clearly, the small number 
of patients enrolled in this trial with as primary endpoint 
safety and feasibility does not allow for firm conclusions 
with regards to clinical outcome. As such, the results from 
this trial should be regarded as hypothesis generating. The 
hypothesis that DCP-001 induces immune responses against 
the patient’s leukemic blasts, translating into clinical benefit 
in immune competent patients who are in CR at the time of 
vaccination, will now be investigated in a multi-center ran-
domized phase II trial in AML patients in CR1.
As a secondary objective, DCP-001-induced immune 
responses were assessed. Allogeneic DC vaccines have 
been shown to induce and support antitumor immunity 
in part through generation of allo-response-induced pro-
inflammatory conditions conducive to Th1 skewing and in 
part through the direct priming of tumor-reactive or cross-
reactive T cells [40, 41]. The observed induction of DTH 
responses against the vaccine and increased post-vaccination 
DTH reactivity in five of the tested patients are in line with 
the induction and boosting of systemic Th1 responses. Both 
CD4 and activated (based on a rise in Granzyme B and TIA 
expression) CD8 T cell responses were induced, as judged 
by immunohistochemistry analyses of biopsies taken from 
the DTH site. Results from in vitro proliferation assays with 
pre- and post-vaccination T cells in response to DCP-001 
were in line with these observations. Vaccination-induced 
proliferative responses were noted upon in vitro restimula-
tion in six out of nine patients, which may have included 
responses to both allogeneic and tumor-associated antigens. 
These DCP-001-induced T cell responses were marked by 
increased release of Th1 cytokines, either alone or combined 
with the release of Th2 and Th17 cytokines. The observa-
tion of  CD8+ T cell proliferative responses to DCP-001 
progenitors in five patients further indicated the induction 
of effector T cells able to respond to leukemic blasts lack-
ing high levels of costimulatory molecules. Vaccination-
induced or enhanced T cell responses to WT-1, PRAME, 
NY-ESO-1, and MAGE-A3 were observed in 4 out of 8 
evaluable patients in this study. Whereas WT-1 and PRAME 
are expressed by DCP-001, NY-ESO-1 and MAGE-A3 are 
not. This suggests that T cell responses may have been both 
directly primed or re-stimulated by DCP-001 (or after cross-
presentation of its contents), or indirectly through bystander 
activation and/or epitope spreading. Overall, these results 
demonstrate the development of cell-mediated immune 
responses to vaccination at all doses tested. Finally, also 
induction of humoral responses were observed to DCP-001, 
its progenitors and importantly, also to autologous leukemic 
blasts. The latter unequivocally demonstrates the induction 
of immunity against autologous AML blasts by the alloge-
neic DCP-001.
DCP-001-induced immune responses were observed in 
patients from all cohorts and not restricted to the higher dose 
levels. Overall T cell reactivity (expressed as ‘T cell score’, 
Table 3) was significantly higher in long-term survivors (> 6 
months). Though more patients would be needed for con-
clusive evidence, this is suggestive of a causal relationship 
between DCP-001-induced antitumor immunity and clini-
cal outcome. Of note, patients with a maintained low blast 
count were more likely to develop an immune response to 
the vaccine, advocating the testing of such immunotherapies 
in patients with less advanced stages of disease.
In conclusion, DCP-001 vaccination in elderly AML 
patients is safe, feasible and leads to the induction or boost-
ing of multifunctional antitumor immunity. In patients with 
CR and stable peripheral T cell rate-prolonged overall sur-
vival was observed (median 36 months). These promising 
data warrant further testing of this allogeneic off-the-shelf 
DC vaccine in AML patients in post-chemotherapy complete 
remission either as monotherapy or in combination with 
hypomethylating agents or immune checkpoint inhibitors.
Acknowledgements The authors thank Anita Stam and Sinéad 
Lougheed for excellent technical assistance.
Author contributions Arjan A. van de Loosdrecht and Gert J. Ossen-
koppele were principial investigators on the study. Sandra van Wetering 
and Tanja D. de Gruijl had primary responsibility for the paper and 
wrote the manuscript. Sandra van Wetering, Tanja D. de Gruijl, Ada 
M. Kruisbeek, Arjan A. van de Loosdrecht and Gert J. Ossenkoppele 
designed the study, experiments and interpreted results. Saskia J.A.M. 
Santegoets, Satwinder Kaur Singh, Malika Koppes and Jorn Kaspers 
performed all experiments. Corien M. Eeltink and Yvonne den Hartog 
contributed to clinical trial coordination.
1517Cancer Immunology, Immunotherapy (2018) 67:1505–1518 
1 3
Funding This work was supported by ZonMW translational program 
Grant PTO951.10.106, and Innovatiekrediet IK10085.
Compliance with ethical standards 
Conflict of interest S. van Wetering, S.K. Singh and A.M. Kruisbeek 
are employees of DCPrime but hold no ownership interests. G.J. Os-
senkoppele is a consultant for Novartis, Pfizer, Bristol Myers-Squibb, 
Johnson & Johnson, Sunesis, Celgene, Karypharm, and Amgen. G.J. 
Ossenkoppele receives research support from Novartis, Johnson & 
Johnson, Celgene, Immunogene, and Becton Dickinson. No potential 
conflicts of interest are applicable to the other authors.
Ethical approval The clinical protocol was approved by the Dutch 
national ethical authority (NL25661.000.09; EudraCT number 2008-
006950-16). Informed consent was obtained from all patients included 
in the study. All procedures followed were in accordance with the ethi-
cal standards of the responsible committee on human experimentation 
(institutional and national) and with the Helsinki Declaration of 1975 
(in its most recently amended version).
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution 4.0 International License (http://creat iveco 
mmons .org/licen ses/by/4.0/), which permits unrestricted use, distribu-
tion, and reproduction in any medium, provided you give appropriate 
credit to the original author(s) and the source, provide a link to the 
Creative Commons license, and indicate if changes were made.
References
 1. Dinmohamed AG, Visser O, van Norden Y et al (2016) Treatment, 
trial participation and survival in adult acute myeloid leukemia: a 
population-based study in the Netherlands, 1989–2012. Leukemia 
30:24–31. https ://doi.org/10.1038/leu.2015.188
 2. Burnett A, Wetzler M, Lowenberg B (2011) Therapeutic advances 
in acute myeloid leukemia. J Clin Oncol 29:487–494. https ://doi.
org/10.1200/JCO.2010.30.1820
 3. Terwijn M, van Putten WL, Kelder A et al (2013) High prognos-
tic impact of flow cytometric minimal residual disease detection 
in acute myeloid leukemia: data from the HOVON/SAKK AML 
42A study. J Clin Oncol 31:3889–3897. https ://doi.org/10.1200/
JCO.2012.45.9628
 4. Dombret H, Gardin C (2016) An update of current treatments 
for adult acute myeloid leukemia. Blood 127:53–61. https ://doi.
org/10.1182/blood -2015-08-60452 0
 5. Geiger TL, Rubnitz JE (2015) New approaches for the immuno-
therapy of acute myeloid leukemia. Discov Med 19:275–284
 6. Sabado RL, Balan S, Bhardwaj N (2017) Dendritic cell-based 
immunotherapy. Cell Res 27:74–95. https ://doi.org/10.1038/
cr.2016.157
 7. Schurch CM, Riether C, Ochsenbein AF (2013) Dendritic cell-
based immunotherapy for myeloid leukemias. Front Immunol 
4:496. https ://doi.org/10.3389/fimmu .2013.00496 
 8. Galluzzi L, Senovilla L, Vacchelli E et al (2012) Trial watch: 
Dendritic cell-based interventions for cancer therapy. Oncoim-
munology 1:1111–1134. https ://doi.org/10.4161/onci.21494 
 9. Butterfield LH (2013) Dendritic cells in cancer immunotherapy 
clinical trials: are we making progress? Front Immunol 4:454. 
https ://doi.org/10.3389/fimmu .2013.00454 
 10. Kajihara M, Takakura K, Kanai T et al (2016) Dendritic cell-based 
cancer immunotherapy for colorectal cancer. World J Gastroen-
terol 22:4275–4286. https ://doi.org/10.3748/wjg.v22.i17.4275
 11. de Gruijl TD, van den Eertwegh AJ, Pinedo HM, Scheper RJ 
(2008) Whole-cell cancer vaccination: from autologous to allo-
geneic tumor- and dendritic cell-based vaccines. Cancer Immu-
nol Immunother 57:1569–1577. https ://doi.org/10.1007/s0026 
2-008-0536-z
 12. Mac Keon S, Ruiz MS, Gazzaniga S, Wainstok R (2015) Den-
dritic cell-based vaccination in cancer: therapeutic implications 
emerging from murine models. Front Immunol 6:243. https ://
doi.org/10.3389/fimmu .2015.00243 
 13. Santegoets SJ, Schreurs MW, Masterson AJ et al (2006) In vitro 
priming of tumor-specific cytotoxic T lymphocytes using allo-
geneic dendritic cells derived from the human MUTZ-3 cell 
line. Cancer Immunol Immunother 55:1480–1490. https ://doi.
org/10.1007/s0026 2-006-0142-x
 14. van de Ven R, Reurs AW, Wijnands PG, van Wetering S, Kruis-
beek AM, Hooijberg E, Scheffer GL, Scheper RJ, de Gruijl 
TD (2012) Exposure of  CD34+ precursors to cytostatic anth-
raquinone-derivatives induces rapid dendritic cell differentia-
tion: implications for cancer immunotherapy. Cancer Immu-
nol Immunother 61:181–191. https ://doi.org/10.1007/s0026 
2-011-1039-x
 15. Santegoets SJ, van den Eertwegh AJ, van de Loosdrecht AA, 
Scheper RJ, de Gruijl TD (2008) Human dendritic cell line mod-
els for DC differentiation and clinical DC vaccination studies. J 
Leukoc Biol 84:1364–1373. https ://doi.org/10.1189/jlb.02080 
92
 16. Santegoets SJ, Stam AG, Lougheed SM et al (2013) T cell profil-
ing reveals high  CD4+ CTLA-4+ T cell frequency as dominant 
predictor for survival after prostate GVAX/ipilimumab treat-
ment. Cancer Immunol Immunother 62:245–256. https ://doi.
org/10.1007/s0026 2-012-1330-5
 17. Santegoets SJ, Bontkes HJ, Stam AG, Bhoelan F, Ruizendaal JJ, 
van den Eertwegh AJ, Hooijberg E, Scheper RJ, de Gruijl TD 
(2008) Inducing antitumor T cell immunity: comparative func-
tional analysis of interstitial versus Langerhans dendritic cells in 
a human cell line model. J Immunol 180:4540–4549
 18. van Houdt IS, Sluijter BJ, Moesbergen LM et al (2008) Favorable 
outcome in clinically stage II melanoma patients is associated 
with the presence of activated tumor infiltrating T-lymphocytes 
and preserved MHC class I antigen expression. Int J Cancer 
123:609–615. https ://doi.org/10.1002/ijc.23543 
 19. van Houdt IS, Sluijter BJ, van Leeuwen PA, Moesbergen LM, 
Hooijberg E, Meijer CJ, de Gruijl TD, Oudejans JJ, Boven E 
(2009) Absence of Granzyme B positive tumour-infiltrating lym-
phocytes in primary melanoma excisional biopsies is strongly 
associated with the presence of sentinel lymph node metastasis. 
Cell Oncol 31:407–413. https ://doi.org/10.3233/CLO-2009-0485
 20. Molenkamp BG, Vuylsteke RJ, van Leeuwen PA, Meijer S, Vos 
W, Wijnands PG, Scheper RJ, de Gruijl TD (2005) Matched skin 
and sentinel lymph node samples of melanoma patients reveal 
exclusive migration of mature dendritic cells. Am J Pathol 
167:1301–1307. https ://doi.org/10.1016/S0002 -9440(10)61217 -5
 21. Bontkes HJ, de Gruijl TD, Walboomers JM, van den Muysen-
berg AJ, Gunther AW, Scheper RJ, Meijer CJ, Kummer JA (1997) 
Assessment of cytotoxic T-lymphocyte phenotype using the 
specific markers granzyme B and TIA-1 in cervical neoplastic 
lesions. Br J Cancer 76:1353–1360
 22. Yuan J, Gnjatic S, Li H et al (2008) CTLA-4 blockade enhances 
polyfunctional NY-ESO-1 specific T cell responses in metastatic 
melanoma patients with clinical benefit. Proc Natl Acad Sci USA 
105:20410–20415. https ://doi.org/10.1073/pnas.08101 14105 
 23. Molenkamp BG, Sluijter BJ, van Leeuwen PA et al (2008) Local 
administration of PF-3512676 CpG-B instigates tumor-specific 
 CD8+ T-cell reactivity in melanoma patients. Clin Cancer Res 
14:4532–4542. https ://doi.org/10.1158/1078-0432.CCR-07-4711
1518 Cancer Immunology, Immunotherapy (2018) 67:1505–1518
1 3
 24. Medinger M, Lengerke C, Passweg J (2016) Novel therapeutic 
options in acute myeloid leukemia. Leuk Res Rep 6:39–49. https 
://doi.org/10.1016/j.lrr.2016.09.001
 25. Fox BA, Schendel DJ, Butterfield LH et al (2011) Defining the 
critical hurdles in cancer immunotherapy. J Transl Med 9:214. 
https ://doi.org/10.1186/1479-5876-9-214
 26. Duiker EW, Meijer A, van der Bilt AR, Meersma GJ, Kooi N, van 
der Zee AG, de Vries EG, de Jong S (2011) Drug-induced caspase 
8 upregulation sensitises cisplatin-resistant ovarian carcinoma 
cells to rhTRAIL-induced apoptosis. Br J Cancer 104:1278–1287. 
https ://doi.org/10.1038/bjc.2011.84
 27. Burnett AK (2013) Treatment of acute myeloid leukaemia. 
Clin Med (London, England). 13(Suppl 6): s58–61. https ://doi.
org/10.7861/clinm edici ne.13-6-s58
 28. Schlenk RF, Dohner H (2013) Genomic applications in the clinic: 
use in treatment paradigm of acute myeloid leukemia. Hematol-
ogy Am Soc Hematol Educ Program 2013:324–330. https ://doi.
org/10.1182/ashed ucati on-2013.1.324
 29. Shokouhi S, Bray S, Bakhtiyari S, Sayehmiri K, Alimoghadam 
K, Ghavamzadeh A (2015) Effects of aGVHD and cGVHD on 
survival rate in patients with acute myeloid leukemia after allo-
geneic stem cell transplantation. Int J Hematol Oncol Stem Cell 
Res 9:112–121
 30. Messerer D, Engel J, Hasford J et al (2008) Impact of differ-
ent post-remission strategies on quality of life in patients with 
acute myeloid leukemia. Haematologica 93:826–833. https ://doi.
org/10.3324/haema tol.11987 
 31. Anguille S, Van Tendeloo VF, Berneman ZN (2012) Leukemia-
associated antigens and their relevance to the immunotherapy of 
acute myeloid leukemia. Leukemia 26:2186–2196. https ://doi.
org/10.1038/leu.2012.145
 32. Keilholz U, Letsch A, Busse A et al (2009) A clinical and immu-
nologic phase 2 trial of Wilms tumor gene product 1 (WT1) 
peptide vaccination in patients with AML and MDS. Blood 
113:6541–6548. https ://doi.org/10.1182/blood -2009-02-20259 8
 33. Schmitt M, Schmitt A, Rojewski MT et al (2008) RHAMM-R3 
peptide vaccination in patients with acute myeloid leukemia, 
myelodysplastic syndrome, and multiple myeloma elicits immu-
nologic and clinical responses. Blood 111:1357–1365. https ://doi.
org/10.1182/blood -2007-07-09936 6
 34. Lee JJ, Kook H, Park MS et al (2004) Immunotherapy using 
autologous monocyte-derived dendritic cells pulsed with leukemic 
cell lysates for acute myeloid leukemia relapse after autologous 
peripheral blood stem cell transplantation. J Clin Apher 19:66–70. 
https ://doi.org/10.1002/jca.10080 
 35. Kitawaki T, Kadowaki N, Fukunaga K et al (2011) Cross-priming 
of CD8(+) T cells in vivo by dendritic cells pulsed with autolo-
gous apoptotic leukemic cells in immunotherapy for elderly 
patients with acute myeloid leukemia. Exp Hematol 39:424 –424 
33 e2. https ://doi.org/10.1016/j.exphe m.2011.01.001
 36. Rosenblatt J, Stone RM, Uhl L et al (2016) Individualized vac-
cination of AML patients in remission is associated with induction 
of antileukemia immunity and prolonged remissions. Sci Transl 
Med 8:368ra171. https ://doi.org/10.1126/scitr anslm ed.aag12 98
 37. Houtenbos I, Westers TM, Ossenkoppele GJ, van de Loosdrecht 
AA (2006) Leukaemic dendritic cell vaccination for patients with 
acute myeloid leukaemia. Br J Haematol 134:445–446. https ://doi.
org/10.1111/j.1365-2141.2006.06196 .x author reply 6–7.
 38. Schumacher TN, Schreiber RD (2015) Neoantigens in cancer 
immunotherapy. Science 348:69–74. https ://doi.org/10.1126/scien 
ce.aaa49 71
 39. Rollig C, Bornhauser M, Thiede C et al (2011) Long-term prog-
nosis of acute myeloid leukemia according to the new genetic 
risk classification of the European LeukemiaNet recommenda-
tions: evaluation of the proposed reporting system. J Clin Oncol 
29:2758–2765. https ://doi.org/10.1200/JCO.2010.32.8500
 40. Andersen BM, Ohlfest JR (2012) Increasing the efficacy of tumor 
cell vaccines by enhancing cross priming. Cancer Lett 325:155–
164. https ://doi.org/10.1016/j.canle t.2012.07.012
 41. Joffre OP, Segura E, Savina A, Amigorena S (2012) Cross-pres-
entation by dendritic cells. Nat Rev Immunol 12:557–569. https 
://doi.org/10.1038/nri32 54
